Observational studyBMC cardiovascular disorders2017
Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Observational study in BMC cardiovascular disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00882336 (Epidemiological Study of European Cardiovascular Risk Patients), which is not on this map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epidemiological Study of European Cardiovascular Risk Patients: Disease Prevention and Management in Usual Daily Practice
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- The association between rapid growth and lipid profile: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Gender-specific relationship between frequency of food-away-from-home with serum lipid levels and dyslipidemia in chinese rural adults.Lipids in health and disease · 2022Trial
- Effectiveness of the Local Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey of Healthcare Professionals and Vaccinees.Pharmacoepidemiology and drug safety · 2026Article
- High Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Hidradenitis Suppurativa: A Guide to Easily Assess the Clinical Risk of Comorbid Liver Disease.JID innovations : skin science from molecules to population health · 2026Article
- Low-Density Lipoprotein Cholesterol Target Attainment in Lithuania: A Nationwide Analysis of Real-World Health Data.Medicina (Kaunas, Lithuania) · 2025Article
- Beyond LDL cholesterol: remnant cholesterol is associated with cardiometabolic risk factors in children.BMC medicine · 2025Article
- Efficacy and safety of dolutegravir plus lamivudine for patients with late presentation of HIV-1 infection: a retrospective real-world cohort study in Southwest China.Frontiers in medicine · 2025Article
- Evaluation of the Effectiveness of Additional Risk Minimisation Measures for Tofacitinib (XeljanzClinical drug investigation · 2024Article
- Article
- Cardiovascular risk and subclinical atherosclerosis in first-degree relatives of patients with premature cardiovascular disease.American journal of preventive cardiology · 2024Article
- Therapeutic Gene Editing in Dyslipidemias.Reviews in cardiovascular medicine · 2024Review
- Prevalence and management of dyslipidemia in primary care practices in Canada.Canadian family physician Medecin de famille canadien · 2024Article
- Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Epidemiology of multimorbidity associated with atherosclerotic cardiovascular disease in the United States, 1999-2018.BMC public health · 2024Article
- Deteriorative Effect of a Combination of Hypertriglyceridemia and Low High-Density Lipoprotein Cholesterolemia on Target Lesion Revascularization after Everolimus-Eluting Stent Implantation.Journal of atherosclerosis and thrombosis · 2023Article
- The Association of Insomnia and Stress on Cardiovascular Risk Factors during COVID-19 Confinement in the Mexican Population.International journal of environmental research and public health · 2023Article
- Can Cardiometabolic Risk Be Reduced in the Elderly? Comprehensive Epidemiological Study.Geriatrics (Basel, Switzerland) · 2023Article
- A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia.Journal of clinical medicine · 2023Review
- High prevalence of dyslipidaemia among persons with diabetes mellitus and hypertension at a tertiary hospital in Blantyre, Malawi.BMC cardiovascular disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-density lipoprotein cholesterol.
methodsThis cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease.
resultsOver 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy.
conclusionsA considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated.
trial registrationThe present study is registered with ClinicalTrials.gov (ID: NCT00882336).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.